-+ 0.00%
-+ 0.00%
-+ 0.00%

ImageneBio Q2 FY26 net loss narrows to $10.2 million; R&D expenses rise to $6.7 million

PUBT·08/05/2026 12:02:17
Listen to the news
ImageneBio Q2 FY26 net loss narrows to $10.2 million; R&D expenses rise to $6.7 million
  • ImageneBio posted a net loss of USD 10.2 million, or USD 0.63 per share, for the quarter ended June 30, 2026.
  • R&D expenses rose 17.54% to USD 6.7 million; G&A costs more than doubled to USD 5.1 million.
  • Cash, cash equivalents and marketable securities totaled USD 136.2 million at June 30, with funding expected into the first quarter of 2028.
  • The Phase 2b ADAPTIVE atopic dermatitis trial continued under an amended protocol, with topline data expected in Q4 2027.
  • An independent monitoring committee backed the study continuing unchanged; a Phase 2 alopecia areata trial is planned to start in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImageneBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050800PRIMZONEFULLFEED9803945) on August 05, 2026, and is solely responsible for the information contained therein.